0.04(0.19%) Volume: 2,057,871 8:08PM EST| Market Cap : 3.55 B | Enterprise Value : 4.63 B | P/E (TTM) : | P/B : 3.83 |
|---|
HZNP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HZNP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 0.43 |
HZNP's Cash-to-Debt is ranked lower than
74% of the 859 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.03 vs. HZNP: 0.43 ) Ranked among companies with meaningful Cash-to-Debt only. |
HZNP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07 Med: 0.6 Max: 2.56 Current: 0.43 |
| Equity-to-Asset | 0.23 |
HZNP's Equity-to-Asset is ranked lower than
91% of the 788 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.64 vs. HZNP: 0.23 ) Ranked among companies with meaningful Equity-to-Asset only. |
HZNP'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77 Med: 0.43 Max: 0.7 Current: 0.23 |
| Debt-to-Equity | 2.06 |
HZNP's Debt-to-Equity is ranked lower than
96% of the 596 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.32 vs. HZNP: 2.06 ) Ranked among companies with meaningful Debt-to-Equity only. |
HZNP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.51 Med: 0.68 Max: 2.21 Current: 2.06 |
| Debt-to-EBITDA | 14.00 |
HZNP's Debt-to-EBITDA is ranked lower than
98% of the 495 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.92 vs. HZNP: 14.00 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
HZNP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.45 Med: -0.52 Max: 14 Current: 14 |
| Piotroski F-Score: 5 |
|
| Altman Z-Score: 0.61 |
|
| Beneish M-Score: -3.10 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -12.60 |
HZNP's Operating Margin % is ranked lower than
76% of the 801 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.97 vs. HZNP: -12.60 ) Ranked among companies with meaningful Operating Margin % only. |
HZNP'
s Operating Margin % Range Over the Past 10 Years
Min: -1841.5 Med: -47.53 Max: 7.31 Current: -12.6 |
| Net Margin % | -18.70 |
HZNP's Net Margin % is ranked lower than
78% of the 802 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.32 vs. HZNP: -18.70 ) Ranked among companies with meaningful Net Margin % only. |
HZNP'
s Net Margin % Range Over the Past 10 Years
Min: -1635.12 Med: -145.04 Max: 5.22 Current: -18.7 |
| ROE % | -22.75 |
HZNP's ROE % is ranked lower than
79% of the 832 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.94 vs. HZNP: -22.75 ) Ranked among companies with meaningful ROE % only. |
HZNP'
s ROE % Range Over the Past 10 Years
Min: -523.78 Med: -82.51 Max: 4.27 Current: -22.75 |
| ROA % | -5.17 |
HZNP's ROA % is ranked lower than
70% of the 871 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.88 vs. HZNP: -5.17 ) Ranked among companies with meaningful ROA % only. |
HZNP'
s ROA % Range Over the Past 10 Years
Min: -186.55 Med: -49.04 Max: 1.89 Current: -5.17 |
| ROC (Joel Greenblatt) % | -737.28 |
HZNP's ROC (Joel Greenblatt) % is ranked lower than
91% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 11.23 vs. HZNP: -737.28 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
HZNP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82 Med: -1847.3 Max: 520.88 Current: -737.28 |
| 3-Year Revenue Growth Rate | 22.20 |
HZNP's 3-Year Revenue Growth Rate is ranked higher than
87% of the 689 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.80 vs. HZNP: 22.20 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
HZNP'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 22.2 Max: 115.5 Current: 22.2 |
| 3-Year EPS without NRI Growth Rate | 7.20 |
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 663 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 8.90 vs. HZNP: 7.20 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
HZNP'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: 7.2 Max: 61.8 Current: 7.2 |
| Steven Cohen 1,312,900 sh (+252.17%) Paul Tudor Jones 137,592 sh (+42.50%) Jim Simons 3,318,600 sh (+45.59%) | John Paulson 7,670,700 sh (-2.54%) |
| Pioneer Investments 442,300 sh (New) Jim Simons 5,014,300 sh (+51.10%) | John Paulson 7,670,700 sh (unchged) | Steven Cohen Sold Out Paul Tudor Jones Sold Out |
| Ken Heebner 150,000 sh (New) Lee Ainslie 299,590 sh (New) Paul Tudor Jones 86,091 sh (New) Jim Simons 6,020,575 sh (+20.07%) | Pioneer Investments 48,000 sh (-89.15%) John Paulson 7,170,700 sh (-6.52%) |
| Jeremy Grantham 11,200 sh (New) Steven Cohen 312,800 sh (New) Jim Simons 6,066,275 sh (+0.76%) Ken Heebner 175,000 sh (+16.67%) Paul Tudor Jones 132,216 sh (+53.58%) | John Paulson 7,170,700 sh (unchged) | Lee Ainslie 285,100 sh (-4.84%) Pioneer Investments 24,200 sh (-49.58%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Action |
Impact | Price Range (Average)* |
Change from Average | Comment | Current Shares |
|---|
What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:HRTX, NAS:MDCO, SHSE:600216, XLJU:KRKG, HKSE:00460, SZSE:002907, SHSE:600267, SHSE:600277, SHSE:603367, SZSE:002737, SZSE:000078, SHSE:600781, SZSE:300199, TSE:4521, BOM:532296, XKRX:041960, NAS:SUPN, XKRX:145020, XTER:EVT, TSE:4555 » details | |
| Traded in other countries: | HPR.Germany, | |
| Headquarter Location: | Ireland |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Forward PE Ratio | 12.06 |
HZNP's Forward PE Ratio is ranked higher than
77% of the 111 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 21.60 vs. HZNP: 12.06 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PB Ratio | 3.83 |
HZNP's PB Ratio is ranked lower than
68% of the 819 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.64 vs. HZNP: 3.83 ) Ranked among companies with meaningful PB Ratio only. |
HZNP'
s PB Ratio Range Over the Past 10 Years
Min: 0.8 Med: 2.31 Max: 14.94 Current: 3.83 |
| PS Ratio | 3.16 |
HZNP's PS Ratio is ranked lower than
52% of the 775 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.10 vs. HZNP: 3.16 ) Ranked among companies with meaningful PS Ratio only. |
HZNP'
s PS Ratio Range Over the Past 10 Years
Min: 1.47 Med: 3.7 Max: 19 Current: 3.16 |
| Price-to-Free-Cash-Flow | 16.81 |
HZNP's Price-to-Free-Cash-Flow is ranked higher than
74% of the 298 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 30.84 vs. HZNP: 16.81 ) Ranked among companies with meaningful Price-to-Free-Cash-Flow only. |
HZNP'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.96 Med: 12.23 Max: 433 Current: 16.81 |
| Price-to-Operating-Cash-Flow | 15.78 |
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 392 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 22.00 vs. HZNP: 15.78 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
HZNP'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.84 Med: 11.45 Max: 209.52 Current: 15.78 |
| EV-to-EBITDA | 34.26 |
HZNP's EV-to-EBITDA is ranked lower than
90% of the 597 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 15.24 vs. HZNP: 34.26 ) Ranked among companies with meaningful EV-to-EBITDA only. |
HZNP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -608 Med: -1 Max: 518 Current: 34.26 |
| EV-to-Revenue | 4.13 |
HZNP's EV-to-Revenue is ranked lower than
59% of the 795 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.24 vs. HZNP: 4.13 ) Ranked among companies with meaningful EV-to-Revenue only. |
HZNP'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5 Med: 4.45 Max: 30.2 Current: 4.13 |
| Current Ratio | 1.94 |
HZNP's Current Ratio is ranked lower than
65% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.39 vs. HZNP: 1.94 ) Ranked among companies with meaningful Current Ratio only. |
HZNP'
s Current Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.73 Max: 4.39 Current: 1.94 |
| Quick Ratio | 1.85 |
HZNP's Quick Ratio is ranked lower than
56% of the 855 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.87 vs. HZNP: 1.85 ) Ranked among companies with meaningful Quick Ratio only. |
HZNP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.56 Max: 4.27 Current: 1.85 |
| Days Inventory | 54.21 |
HZNP's Days Inventory is ranked higher than
81% of the 755 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 119.80 vs. HZNP: 54.21 ) Ranked among companies with meaningful Days Inventory only. |
HZNP'
s Days Inventory Range Over the Past 10 Years
Min: 13.1 Med: 78.91 Max: 201.46 Current: 54.21 |
| Days Sales Outstanding | 126.76 |
HZNP's Days Sales Outstanding is ranked lower than
82% of the 770 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 81.76 vs. HZNP: 126.76 ) Ranked among companies with meaningful Days Sales Outstanding only. |
HZNP'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08 Med: 96.16 Max: 126.94 Current: 126.76 |
| Days Payable | 50.68 |
HZNP's Days Payable is ranked lower than
90% of the 758 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 76.32 vs. HZNP: 50.68 ) Ranked among companies with meaningful Days Payable only. |
HZNP'
s Days Payable Range Over the Past 10 Years
Min: 23.17 Med: 140.69 Max: 410.36 Current: 50.68 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.80 |
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 571 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -5.30 vs. HZNP: -9.80 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
HZNP'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1 Med: -84.9 Max: -9.8 Current: -9.8 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 1.30 | ||
| Price-to-Median-PS-Value | 0.85 |
HZNP's Price-to-Median-PS-Value is ranked higher than
59% of the 743 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.94 vs. HZNP: 0.85 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
HZNP'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47 Med: 1.01 Max: 4.57 Current: 0.85 |
| Earnings Yield (Greenblatt) % | -3.05 |
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 867 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.31 vs. HZNP: -3.05 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
HZNP'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -913.1 Med: -5.15 Max: 2.6 Current: -3.05 |
| Revenue (TTM) (Mil) $ | 1,126.25 |
|---|---|
| EPS (TTM) $ | -1.29 |
| Beta | 0.95 |
| Volatility | 35.58% |
| 52-Week Range $ | 12.55 - 24.03 |
| Shares Outstanding (Mil) | 167.63 |
| Dec18 | Dec19 | |
|---|---|---|
| Revenue (Mil $) | ||
| EBIT (Mil $) | ||
| EBITDA (Mil $) | ||
| EPS ($) | 1.60 | 1.76 |
| EPS without NRI ($) | 1.60 | 1.76 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | |
| Dividends per Share ($) | ||
|
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP